Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Eye · 2025

Vizz (aceclidine)

The FDA approved Vizz (aceclidine) on July 31, 2025 to treat presbyopia.
Brand name
Vizz
Generic name
aceclidine
FDA approval date
July 31, 2025
Approved use (FDA wording)
To treat presbyopia
Company
Lenz Therap
Application
NDA218585
Dosage form / route
SOLUTION/DROPS · OPHTHALMIC
Boxed warning on label
Not listed
Category on this site
Eye

Indications and usage, from the FDA label

VIZZ is indicated for the treatment of presbyopia in adults. VIZZ is a cholinergic agonist indicated for the treatment of presbyopia in adults ( 1 ).

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.